Bruker–Leucadia: investor conference, 202211 supply service Bruker presents at Jefferies 2022 London Healthcare Conference

	Period	2022-11-15
	Region	London, Greater London
	Country	United Kingdom (GB)
	Partner, 1st	Bruker Corporation (Nasdaq: BRKR)
	Group	Bruker (Group)
	Partner, 2nd	Jefferies International Ltd.
	Group	Leucadia (Group)
	Product	Jefferies 2022 London Healthcare Conference
	Product 2	analytical instrument

Bruker Corporation. (11/7/22). "Press Release: Bruker Corporation to Participate in the 2022 Jefferies London Healthcare Conference". Billerica, MA.

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2022 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 15, 2022 at 12:00 PM Eastern Time.

A live audio webcast of the question and answer session will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 90 days.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
+1 (978) 663–3660, ext. 1479
Investor.Relations@bruker.com